Showing results (41-50 of 621) with videos related to
Sort By:
Pageof 63
Journal of Neurology|May 28, 2022
Resurrection of sildenafil: potential for Huntington's Disease, too?Jannis Achenbach, Simon Faissner, Carsten SaftFrontiers in Immunology|June 7, 2022
Contemplating Dichotomous Nature of Gamma Delta T Cells for ImmunotherapyJaydeep Bhat, Katarzyna Placek, Simon FaissnerBrain Sciences|April 3, 2021
Longitudinal Evaluation of the Effect of Tricyclic Antidepressants and Neuroleptics on the Course of Huntington's Disease-Data from a Real World CohortJannis Achenbach, Carsten Saft, Simon FaissnerJournal of Neuroinflammation|June 16, 2018
Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis modelAnna T Wilmes, Sabrina Reinehr, Sandra Kühn, et al.Frontiers in Immunology|May 1, 2025
The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigmRobert Hoffrogge, Anna Karachunskaya, Neele Heitmann, et al.Journal of Neurology|July 22, 2024
Quality of life and tolerability of B-cell directed therapy of multiple sclerosis with ofatumumab in a patient-centered real-world observational studyAnna-Sophia Karl, Rafael Klimas, Melina Katsimpoura, et al.Therapeutic Advances in Neurological Disorders|December 15, 2022
Preserved T-cell response in anti-CD20-treated multiple sclerosis patients following SARS-CoV-2 vaccinationSimon Faissner, Neele Heitmann, Ricarda Rohling, et al.Experimental Neurology|August 24, 2014
Cytoplasmic HIV-RNA in monocytes determines microglial activation and neuronal cell death in HIV-associated neurodegenerationSimon Faissner, Björn Ambrosius, Kirsten Schanzmann, et al.Expert Opinion on Drug Metabolism & Toxicology|February 11, 2011
Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosisJan Thöne, Ralf GoldDer Nervenarzt|March 3, 2021
[Disease-modifying treatment of secondary progressive multiple sclerosis]Olaf Hoffmann, Ralf GoldPageof 63